A Randomized Trial of the N-Methyl-d-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression

Depression in the Primary Care Setting

(2019) Lawrence T. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo–control study

(2019) Mu-Hong Chen et al.   NEUROPSYCHOPHARMACOLOGY

Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review

(2018) P. Molero et al.   CNS DRUGS

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms

(2018) Panos Zanos et al.   PHARMACOLOGICAL REVIEWS

The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?

(2018) Chadi G. Abdallah et al.   PHARMACOLOGY & THERAPEUTICS

Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects

(2018) Ruin Moaddel et al.   PSYCHOPHARMACOLOGY

Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants

(2018) Todd D. Gould et al.   Annual Review of Pharmacology and Toxicology

Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments

(2018) Bashkim Kadriu et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Characterization of the Effects of L-4-Chlorokynurenine on Nociception in Rodents

(2017) Tony L. Yaksh et al.   JOURNAL OF PAIN

Targeting glutamate signalling in depression: progress and prospects

(2017) James W. Murrough et al.   NATURE REVIEWS DRUG DISCOVERY

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

(2016) Panos Zanos et al.   NATURE

Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studies

(2015) Gislaine Z. Réus et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial

(2013) James W. Murrough et al.   AMERICAN JOURNAL OF PSYCHIATRY

Conceptual Confluence: The Kynurenine Pathway as a Common Target for Ketamine and the Convergence of the Inflammation and Glutamate Hypotheses of Depression

(2013) Andrew H Miller   NEUROPSYCHOPHARMACOLOGY

Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial

(2012) Carlos A. Zarate et al.   BIOLOGICAL PSYCHIATRY

A randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression

(2012) Uriel Heresco-Levy et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression

(2010) Nancy Diazgranados et al.   ARCHIVES OF GENERAL PSYCHIATRY

Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression

(2009) Marije aan het Rot et al.   BIOLOGICAL PSYCHIATRY